{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:28:33Z","timestamp":1761823713768},"reference-count":24,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2015,5,22]],"date-time":"2015-05-22T00:00:00Z","timestamp":1432252800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"The Medicines Company (Parsippany, NJ)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cathet Cardio Intervent"],"published-print":{"date-parts":[[2016,2,15]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Outcomes with bivalirudin compare favorably with heparin\u2009\u00b1\u2009GPIIb\/IIIa receptor inhibition (heparin\u2009\u00b1\u2009GPI) during percutaneous coronary intervention (PCI). Patients with congestive heart failure (CHF) have increased risk for complications. The objective was to investigate clinical and economic outcomes for bivalirudin\u2009\u00b1\u2009GPI vs. heparin\u2009\u00b1\u2009GPI among PCI patients with CHF.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Using the Premier Hospital Database, PCI patients with CHF were stratified by anticoagulant: bivalirudin, bivalirudin\u2009\u00b1\u2009GPI, heparin and heparin\u2009\u00b1\u2009GPI. The probability of receiving bivalirudin\u2009\u00b1\u2009GPI was estimated using individual and hospital variables. Using propensity scores, each bivalirudin\u2009\u00b1\u2009GPI patient was matched to a heparin\u2009\u00b1\u2009GPI patient. The primary outcome was in\u2010hospital death. Bleeding rates, transfusion, length of stay and in\u2010hospital cost were ascertained.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 116,313 patients at 315 hospitals received bivalirudin (<jats:italic>n<\/jats:italic>\u2009=\u200945,559) bivalirudin\u2009+\u2009GPI (<jats:italic>n<\/jats:italic>\u2009=\u20098,115), heparin (<jats:italic>n<\/jats:italic>\u2009=\u200927,972) or heparin\u2009+\u2009GPI (<jats:italic>n<\/jats:italic>\u2009=\u200934,667). Patients had STEMI (21.2%), NSTEMI (29.1%), unstable angina (16.6%), stable angina (5.7%) or other ischemic heart disease (24.2%). Of these, 79.1% of bivalirudin patients matched, resulting in 84,948 analyzed patients. Compared with heparin\u2009\u00b1\u2009GPI patients, bivalirudin\u2009\u00b1\u2009GPI patients had fewer deaths (3.3% vs. 3.9%; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), less clinically apparent bleeding (10.2% vs. 11.4%; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), clinically apparent bleeding with transfusion (2.7% vs. 3.2%, <jats:italic>p<\/jats:italic> &lt;0.0001), and transfusion (8.5% vs. 9.8%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). Patients receiving bivalirudin had shorter length of stay (6.3 vs. 6.8 days; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) and lower in\u2010hospital cost (mean $26,706 vs. $27,166 [median $19,414 vs. $19,798]; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). In conclusion, this is the largest retrospective analysis of PCI patients with CHF and demonstrates bivalirudin\u2009\u00b1\u2009GPI compared with heparin\u2009\u00b1\u2009GPI is associated with lower inpatient rates of death, bleeding, and cost. \u00a9 2015 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/ccd.26023","type":"journal-article","created":{"date-parts":[[2015,5,22]],"date-time":"2015-05-22T12:54:52Z","timestamp":1432299292000},"page":"363-373","source":"Crossref","is-referenced-by-count":2,"title":["Bivalirudin is associated with improved clinical and economic outcomes in heart failure patients undergoing percutaneous coronary intervention: Results from an observational database"],"prefix":"10.1002","volume":"87","author":[{"given":"Duane S.","family":"Pinto","sequence":"first","affiliation":[{"name":"Cardiology Division Beth Israel Deaconess Medical Center and Harvard Medical School Boston Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Payal","family":"Kohli","sequence":"additional","affiliation":[{"name":"Cardiology Division University of California  San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weihong","family":"Fan","sequence":"additional","affiliation":[{"name":"The Medicines Company Parsippany New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay J.","family":"Kirtane","sequence":"additional","affiliation":[{"name":"Columbia University Medical Center\/New York Presbyterian Hospital and Cardiovascular Research Foundation New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert D.","family":"Kociol","sequence":"additional","affiliation":[{"name":"Cardiology Division Beth Israel Deaconess Medical Center and Harvard Medical School Boston Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Meduri","sequence":"additional","affiliation":[{"name":"Cardiology Division Beth Israel Deaconess Medical Center and Harvard Medical School Boston Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Efthymios N.","family":"Deliargyris","sequence":"additional","affiliation":[{"name":"The Medicines Company Parsippany New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayne","family":"Prats","sequence":"additional","affiliation":[{"name":"The Medicines Company Parsippany New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew R.","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Lahey Clinic Burlington, MA and Harvard Clinical Research Institute Boston Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregg W.","family":"Stone","sequence":"additional","affiliation":[{"name":"Columbia University Medical Center\/New York Presbyterian Hospital and Cardiovascular Research Foundation New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Michael Gibson","sequence":"additional","affiliation":[{"name":"Cardiology Division Beth Israel Deaconess Medical Center and Harvard Medical School Boston Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,5,22]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000109691.16944.DA"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0195-668X(03)00485-8"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs295"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2005.03.053"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2003.182"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2007.12.005"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/14.2.205"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2012.12.018"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062437"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.7.853"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708191"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61216-2"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0707571"},{"key":"e_1_2_6_15_1","first-page":"476","article-title":"The ratio of costs to charges: How good a basis for estimating costs?","volume":"32","author":"Shwartz M","year":"1995","journal-title":"Inquiry"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.2307\/2683903"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B"},{"key":"e_1_2_6_18_1","article-title":"Local and Global Optimal Propensity Score Matching","author":"Coca\u2010Perraillon M.","year":"2007","journal-title":"Proceedings of the SAS Global Forum"},{"key":"e_1_2_6_19_1","unstructured":"CohenJ.Statistical Power Analysis for the Behavioral Sciences;1977."},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2328"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.612812"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.878017"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2009.05.004"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.694273"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60924-7"}],"container-title":["Catheterization and Cardiovascular Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fccd.26023","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ccd.26023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T18:06:10Z","timestamp":1696615570000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ccd.26023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,22]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,2,15]]}},"alternative-id":["10.1002\/ccd.26023"],"URL":"https:\/\/doi.org\/10.1002\/ccd.26023","archive":["Portico"],"relation":{},"ISSN":["1522-1946","1522-726X"],"issn-type":[{"value":"1522-1946","type":"print"},{"value":"1522-726X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,22]]}}}